Evidence map›Paper›PMID 38571813›Full record

ArticleFrontiers in molecular neuroscience2024

Structural and functional characterization of the IgSF21-neurexin2α complex and its related signaling pathways in the regulation of inhibitory synapse organization.

Nicolas Chofflet, Yusuke Naito, Anthony John Pastore, Nirmala Padmanabhan, Phuong Trang Nguyen, Christian Poitras, Benjamin Feller, Nayoung Yi, Jeremie Van Prooijen, Husam Khaled and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Alpha-neurexins in health and disease.Frontiers in molecular neuroscience · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 3 countries.

Nicolas ChoffletSynapse Development and Plasticity Research Unit, Institut de Recherches Cliniques de Montréal, Montreal, QC, Canada.
Yusuke NaitoSynapse Development and Plasticity Research Unit, Institut de Recherches Cliniques de Montréal, Montreal, QC, Canada.
Anthony John PastoreDepartment of Pharmacology and Toxicology, Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, United States.
Nirmala PadmanabhanPrairieNeuro Research Centre, Health Sciences Centre, Kleysen Institute for Advanced Medicine, Winnipeg, MB, Canada.
Phuong Trang NguyenQuebec Network for Research on Protein Function, Engineering and Applications (PROTEO), Department of Chemistry, Université du Québec à Montréal, Montreal, QC, Canada.
Christian PoitrasDepartment of Translational Proteomics, Institut de Recherches Cliniques de Montréal, Montreal, QC, Canada.
Benjamin FellerSynapse Development and Plasticity Research Unit, Institut de Recherches Cliniques de Montréal, Montreal, QC, Canada.
Nayoung YiSynapse Development and Plasticity Research Unit, Institut de Recherches Cliniques de Montréal, Montreal, QC, Canada.
Jeremie Van ProoijenSynapse Development and Plasticity Research Unit, Institut de Recherches Cliniques de Montréal, Montreal, QC, Canada.
Husam KhaledSynapse Development and Plasticity Research Unit, Institut de Recherches Cliniques de Montréal, Montreal, QC, Canada.
Benoit CoulombeDepartment of Translational Proteomics, Institut de Recherches Cliniques de Montréal, Montreal, QC, Canada.
Steven J ClapcoteSchool of Biomedical Sciences, University of Leeds, Leeds, United Kingdom.
Steve BourgaultQuebec Network for Research on Protein Function, Engineering and Applications (PROTEO), Department of Chemistry, Université du Québec à Montréal, Montreal, QC, Canada.
Tabrez J SiddiquiPrairieNeuro Research Centre, Health Sciences Centre, Kleysen Institute for Advanced Medicine, Winnipeg, MB, Canada.
Gabby RudenkoDepartment of Pharmacology and Toxicology, Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, United States.
Hideto TakahashiSynapse Development and Plasticity Research Unit, Institut de Recherches Cliniques de Montréal, Montreal, QC, Canada.
Montreal Clinical Research Institute · CAThe University of Texas Medical Branch at Galveston · USHealth Sciences Centre · CAMcGill University · CAPROTEO · CAUniversité de Montréal · CAUniversité du Québec à Montréal · CAUniversity of Leeds · GBUniversity of Manitoba · CA

Funding

Synaptic Organizers: Dynamic Regulation of Trans-synaptic BridgesR01MH077303 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Gabrielle Rudenko · 2006 to 2026
$8.2M
Predoctoral and Postdoctoral Training in Alzheimer's PathophysiologyT32AG067952 · NIA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI KAYED, RAKEZ · 2021 to 2025
$1.5M
NIA NIH HHS T32 AG067952NIMH NIH HHS R01 MH077303
6 · The paper itself

Abstract

The prevailing model behind synapse development and specificity is that a multitude of adhesion molecules engage in transsynaptic interactions to induce pre- and postsynaptic assembly. How these extracellular interactions translate into intracellular signal transduction for synaptic assembly remains unclear. Here, we focus on a synapse organizing complex formed by immunoglobulin superfamily member 21 (IgSF21) and neurexin2α (Nrxn2α) that regulates GABAergic synapse development in the mouse brain. We reveal that the interaction between presynaptic Nrxn2α and postsynaptic IgSF21 is a high-affinity receptor-ligand interaction and identify a binding interface in the IgSF21-Nrxn2α complex. Despite being expressed in both dendritic and somatic regions, IgSF21 preferentially regulates dendritic GABAergic presynaptic differentiation whereas another canonical Nrxn ligand, neuroligin2 (Nlgn2), primarily regulates perisomatic presynaptic differentiation. To explore mechanisms that could underlie this compartment specificity, we targeted multiple signaling pathways pharmacologically while monitoring the synaptogenic activity of IgSF21 and Nlgn2. Interestingly, both IgSF21 and Nlgn2 require c-jun N-terminal kinase (JNK)-mediated signaling, whereas Nlgn2, but not IgSF21, additionally requires CaMKII and Src kinase activity. JNK inhibition diminished

Indexed as

CaMKII kinasec-jun N-terminal kinaseGABAergic synapseIgSF21neurexin2αneuroligin2signal transductionSrc kinase

Identifiers

PMID38571813
PMCPMC10989685
OpenAlexW4392986190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.